Ann: MOU with Temasek-linked Innoventures - Orthopaedics in China, page-12

Dont know.

But you have to wonder about sellers sometimes. We are 1/10th the price we were in 2019 says the CEO, now at the pointy end, low cap, with china expansion agenda, and revenues growth occurring in other parts of the world. The nature of a better light bulb, one that does not have the infection complications of the incumbents, is going to develop organic momentum. Patient outcomes, better health, its not a hard pitch to make, and by referrals of doctors who are using it, are going to be both repeat sales, and sales agents in effect when they talk to their colleagues.

I can imagine the emotional journey that longer holders have endured, seeing value wiped off their paper in the last few years, but that is the risk of the fickle investor who is impatient, and shifts the price, until, having crossed that wilderness, that desert, and now makes the RVR weighted heavily to cheap entry, and catching the forward growth curve. We are 3-4 years on, with regulatory approvals in place, and moving ahead.

Sometimes a great product, that is valued well by the market initially, runs into head winds. That doesnt prevent it from catching a tail wind after it has been harbored for some time.

Not investment advice.